RX.V / BIOYF continues to be a potential multi-bag
Post# of 428
RX.V / BIOYF continues to be a potential multi-bagger home run IMO. Here's why:
(1) RX.V / BIOYF is debt-free, cash-rich making money hand over fist compared to its tiny market cap and growing rapidly. Their key product, Feramax, is getting rave reviews by pharmacists, doctors, and users. They continue to expand with several new products that are showing early signs of great success.
(2) Last quarter they had +.024 EPS. Annualized + growth makes them appear cheap to me especially vs. future increased potential EPS.
(3) Their profit margins are extremely high.
(4) RX.V / BIOYF launched a new product recently in addition to another product for its Feramax line. The new product, Cathejell, already has two long term hospital supply contracts.
(5) RX.V / BIOYF also launched an expansion of their Feramax family of products. Given the success of this line already, I expect different formulations to also help expand this success.
(6) RX.V / BIOYF also announced that two new products are coming, pending Health Canada approval for launch.
(7) Insiders have bought shares in the open market several times.
(0)
(0)